At a glance
ClinicalIndex Comparison Record- ✓Confirmed diagnosis of B-cell CLL with peripheral blood lymphocytosis >5,000/mm³
- ✓Co-expression of CD5, CD19 or CD20, and CD23 surface antigens
- ✓Clonal kappa or lambda light chain expression
- ✓Newly diagnosed (no prior CLL therapy)
- ✕Recurrent or refractory CLL
- ✕Other lymphoproliferative diseases or CLL transformation (e.g., prolymphocytic leukemia, Richter's syndrome)
- ✕Cardiac arrhythmia within past 6 months
- ✕Myocardial infarction within past 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of Fludarabine Plus Thalidomide as Frontline Therapy for Newly Diagnosed Patients With Chronic Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating fludarabine phosphate and thalidomide for Leukemia. Completed, enrolled 43 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies such as thalidomide use different ways to stimulate the immune system and stop cancer cells from growing. Combining fludarabine with thalidomide may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of thalidomide when given together with fludarabine and to see how well they work in treating patients with newly diagnosed B-cell chronic lymphocytic leukemia.
Study Details
Timeline
Interventions
Given IV
Orally